Watch for the VALTOCO orphan exclusivity expiration on January 10, 2027, which triggers LIBERVANT's eligibility for full FDA approval in patients 12+. The PDUFA date for the ages 6-11 label expansion is March 29, 2027. Commercial launch is expected in April 2027 — monitor for pre-launch stocking orders and physician adoption signals.
Price Chart
Executive Summary
Eton Pharmaceuticals entered into an exclusive U.S. license and supply agreement with Aquestive Therapeutics for LIBERVANT (diazepam) buccal film, a differentiated seizure rescue treatment targeting a >$450M annual U.S. market. Eton paid a $10M upfront fee and will owe up to $47.5M in regulatory/commercial milestones plus mid-teens royalties. The product has tentative FDA approval and is expected to launch in April 2027 after VALTOCO's orphan exclusivity expires in January 2027. This adds a near-term commercial neurology platform to Eton's rare disease portfolio.
Key Financial Metrics
Key Facts
- Eton paid Aquestive a $10.0 million upfront license fee for exclusive U.S. commercialization rights to LIBERVANT (diazepam) buccal film.
- Total milestone payments to Aquestive are up to $47.5 million: $10M ($5M reduced) on first commercial sale, $2.5M on FDA approval for ages 6-11, and up to $35M in commercial sales milestones.
- Eton will pay Aquestive tiered royalties at a mid-teens percentage rate on annual net sales of LIBERVANT.
- LIBERVANT has tentative FDA approval for ages 2-5 and 12+; full approval for 12+ expected after VALTOCO's orphan exclusivity expires on January 10, 2027.
- A Type 9 NDA to expand the label to ages 6-11 has a PDUFA target action date of March 29, 2027.
- Anticipated commercial launch in April 2027, subject to final FDA approval.
- The U.S. seizure rescue market exceeds $450 million annually.
- LIBERVANT has orphan drug designation and patent protection extending into 2038.
- Supply agreement has an initial term of 20 years with automatic renewal for three-year periods.
- Patient market research showed 71% of surveyed patients preferred buccal film over nasal spray (13%) assuming equivalent efficacy.
Financial Impact
Eton paid $10M upfront; total potential milestone payments of $47.5M plus mid-teens royalties. The target market exceeds $450M annually in the U.S.
Risk Factors
- Final FDA approval is still required; launch could be delayed if VALTOCO exclusivity or regulatory issues arise.
- Competition from existing nasal (VALTOCO) and rectal (DIASTAT) rescue treatments may limit market share.
- Milestone and royalty payments reduce net margin on LIBERVANT sales.
- Commercial execution risk: Eton must build a neurology sales team and establish market access.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-032600 |
| Document: eton20261013_8k.htm | 0001437749-26-032600 |
| Document: 0001437749-26-032600-index-headers.html | 0001437749-26-032600 |
| Document: 0001437749-26-032600-index.html | 0001437749-26-032600 |
| Document: 0001437749-26-032600.txt | 0001437749-26-032600 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $52.88 | awaiting T+60 | — | $50.17 (−5.12%) |
Oct 6, 2026 20d ago | 144 | $54.88 | awaiting T+60 | — | $50.17 (−8.58%) |
Sep 28, 2026 28d ago | 8-K | $59.18 | awaiting T+60 | — | $50.17 (−15.22%) |
Aug 31, 2026 8w ago | Insider Cluster | $60.43 | awaiting T+60 | — | $50.17 (−16.98%) |
Aug 28, 2026 8w ago | Insider Cluster | $60.44 | awaiting T+60 | — | $50.17 (−16.99%) |
Aug 24, 2026 9w ago | Insider Cluster | $63.05 | awaiting T+60 | — | $50.17 (+20.43%) |
Aug 19, 2026 9w ago | 144 | $61.48 | awaiting T+60 | — | $50.17 (+18.40%) |
Aug 5, 2026 11w ago | 8-K | $45.97 | awaiting T+60 | — | $50.17 (+9.14%) |
Aug 5, 2026 11w ago | Press Release | $45.97 | awaiting T+60 | — | $50.17 (+9.14%) |
Aug 4, 2026 11w ago | 8-K | $45.83 | awaiting T+60 | — | $50.17 (+9.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers